Prothena Corporation plc has announced that Novo Nordisk will advance coramitug, formerly known as PRX004, into Phase 3 development for the treatment of ATTR amyloidosis with cardiomyopathy. Coramitug is a potential first-in-class amyloid depleter antibody. Novo Nordisk completed a Phase 2 trial successfully and plans to initiate the Phase 3 program in 2025. Prothena is set to earn a clinical milestone payment upon meeting prespecified enrollment criteria in the Phase 3 clinical trial. Results of the Phase 3 trial have not yet been presented and are anticipated in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.